Australian Trade Mark Search

Australian Trade Mark Search is the Australian Government’s trade mark search system.

Australian Government IP Australia
Additional fields:

Trade mark 1943207

Words ALNYLAM
Image
Image description
Status registered: Registered/protected
Priority date 18 May 2018 (Convention)
Class 5
Kind Word
Dates
Renewal due 24 Jul 2028
Registration advertised / published 18 Dec 2018
Entered on Register 18 Dec 2018
Acceptance advertised / published 11 Oct 2018
Acceptance 16 Aug 2018
Filing 24 Jul 2018
Registered from 24 Jul 2018

Owner Address for service
Alnylam Pharmaceuticals, Inc.
a corporation of Delaware
Corrs Chambers Westgarth

Goods & Services
Class 5: Pharmaceutical preparations, namely, RNA therapeutics for use in the treatment of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection; Pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes for use in the treatment of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection; pharmaceutical preparations, namely, RNA therapeutics; pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes

Endorsements

Convention details
Date 18 May 2018
Number 87927601
Country UNITED STATES OF AMERICA
Description CONVENTION PRIORITY CLAIMED: 18 MAY 2018, UNITED STATES OF AMERICA, NO. 87927601 IN RESPECT OF PHARMACEUTICAL PREPARATIONS, NAMELY, RNA THERAPEUTICS FOR USE IN THE TREATMENT OF CANCER, HIV, HEPATITIS A, HEPATITIS B, INFLUENZA, MEASLES, NEURODEGENERATIVE DISEASES, TRANSTHYRETIN (TTR)-MEDIATED AMYLOIDOSIS (ATTR), HEMOPHILIA, PORPHYRIA, COMPLEMENT-MEDIATED DISEASE, HYPERCHOLESTEROLEMIA, RARE GENETIC DISEASES, CARDIO-METABOLIC DISEASES, HEPATIC INFECTIOUS DISEASES, HEREDITARY ATTR AMYLOIDOSIS, RARE BLEEDING DISORDERS, HEPATIC PORPHYRIAS, ALPHA-1 ANTITRYPSIN DEFICIENCY, PRIMARY HYPEROXALURIA TYPE 1, BETA-THALASSEMIA, IRON OVERLOAD DISORDERS, HEREDITARY ANGIODEMA, HYPERTRIGLYCERIDEMIA, MIXED HYPERLIPIDEMIA, HYPERTRIGLYCERIDEMIA, HYPERTENSION, PREECLAMPSIA, THROMBOPROPHYLAXIS, HEPATITIS B VIRUS INFECTION, HEPATITIS D VIRUS INFECTION, CHRONIC LIVER INFECTION; PHARMACEUTICALS, BIOSIMILARS AND BIOLOGICAL PREPARATIONS FOR MEDICAL AND THERAPEUTIC PURPOSES FOR USE IN THE TREATMENT OF CANCER, HIV, HEPATITIS A, HEPATITIS B, INFLUENZA, MEASLES, NEURODEGENERATIVE DISEASES, TRANSTHYRETIN (TTR)-MEDIATED AMYLOIDOSIS (ATTR), HEMOPHILIA, PORPHYRIA, COMPLEMENT-MEDIATED DISEASE, HYPERCHOLESTEROLEMIA, RARE GENETIC DISEASES, CARDIO-METABOLIC DISEASES, HEPATIC INFECTIOUS DISEASES, HEREDITARY ATTR AMYLOIDOSIS, RARE BLEEDING DISORDERS, HEPATIC PORPHYRIAS, ALPHA-1 ANTITRYPSIN DEFICIENCY, PRIMARY HYPEROXALURIA TYPE 1, BETA-THALASSEMIA, IRON OVERLOAD DISORDERS, HEREDITARY ANGIODEMA, HYPERTRIGLYCERIDEMIA, MIXED HYPERLIPIDEMIA, HYPERTRIGLYCERIDEMIA, HYPERTENSION, PREECLAMPSIA, THROMBOPROPHYLAXIS, HEPATITIS B VIRUS INFECTION, HEPATITIS D VIRUS INFECTION, CHRONIC LIVER INFECTION; PHARMACEUTICAL PREPARATIONS, NAMELY, RNA THERAPEUTICS; PHARMACEUTICALS, BIOSIMILARS AND BIOLOGICAL PREPARATIONS FOR MEDICAL AND THERAPEUTIC PURPOSES IN CLASS 5.

Indexing constituents
Word Image